We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical translation of patient-derived tumour organoids- bottlenecks and strategies.
- Authors
Foo, Malia Alexandra; You, Mingliang; Chan, Shing Leng; Sethi, Gautam; Bonney, Glenn K.; Yong, Wei-Peng; Chow, Edward Kai-Hua; Fong, Eliza Li Shan; Wang, Lingzhi; Goh, Boon-Cher
- Abstract
Multiple three-dimensional (3D) tumour organoid models assisted by multi-omics and Artificial Intelligence (AI) have contributed greatly to preclinical drug development and precision medicine. The intrinsic ability to maintain genetic and phenotypic heterogeneity of tumours allows for the reconciliation of shortcomings in traditional cancer models. While their utility in preclinical studies have been well established, little progress has been made in translational research and clinical trials. In this review, we identify the major bottlenecks preventing patient-derived tumour organoids (PDTOs) from being used in clinical setting. Unsuitable methods of tissue acquisition, disparities in establishment rates and a lengthy timeline are the limiting factors for use of PDTOs in clinical application. Potential strategies to overcome this include liquid biopsies via circulating tumour cells (CTCs), an automated organoid platform and optical metabolic imaging (OMI). These proposed solutions accelerate and optimize the workflow of a clinical organoid drug screening. As such, PDTOs have the potential for potential applications in clinical oncology to improve patient outcomes. If remarkable progress is made, cancer patients can finally benefit from this revolutionary technology.
- Publication
Biomarker Research, 2022, Vol 10, Issue 1, p1
- ISSN
2050-7771
- Publication type
Article
- DOI
10.1186/s40364-022-00356-6